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Introduction
Mutations of CERC1 have been recently reported as causa-
tive of an inflammatory condition characterized by polyar-
teritis, cerebral stroke and immunodeficiency; the response
to immunosuppressors and biological drugs is not univocal.
Aim of the study
To describe a series of patients with DADA2, focusing
on the response to treatment and outcome.
Patients and methods
Patients with a clinical history consistent with a possible
DADA2 were retrospectively analyzed; molecular analysis
of the CECR1 gene was performed. Detailed analysis of
the clinical presentation, disease course and response to
treatment was retrospectively performed in patients with
confirmed diagnosis.
Results
The retrospective analysis of patients allowed to identify 5
patients presenting with a strong clinical suspicion of
DADA2. The mean age of disease onset was 12 months
(range 6-36). The disease course was chronic in two
patients and recurrent in three. All patients presented skin
involvement and elevation of acute phase reactants; three
patients presented multiple strokes, one patient acute
invagination of the small bowel. Skin biopsy was consis-
tent with PAN in three patients.
The molecular analysis of CECR1 gene identified homozy-
gosis or compound heterozygosis for deleterious mutations
(G47R, G47A, P251L, R312X, E328D, T360A) in all patients.
All patients required high doses of steroids to control
the skin manifestations and the systemic inflammatory fea-
tures but a clinical relapse was observed at the time of
steroid tapering. In two patients thalidomide was able to
completely control the disease manifestations while one
patient presented a partial response. Other immunosup-
pressant (oral cyclophosphamide and cyclosporine) were
not able to control the disease activity; treatment with ana-
kinra was tempted in one patient, without clinical
improvement. After the suspension of thalidomide and the
failure of cyclophosphamide, etanercept was started in one
patient on may 2008 at the dose of 0.8 mg/kg/daily. The
patients presented a rapid and complete control of
the skin manifestations with a rapid normalization of
acute phase reactants, despite the withdrawal of steroidal
treatment. The same brilliant response to etanercept was
also observed in the brother and, more recently, in other
three patients. The median duration of treatment with
anti-TNF agents is now 34 months (range 6 months-7
years). All 5 patients display a complete control of clinical
manifestations and laboratory parameters and are off from
any steroid treatment. No severe infectious or other com-
plications have been described so far.
Conclusion
This series of 5 patients with DADA2 enlightens the long-
term efficacy of anti-TNF agents.
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